This page is using European product trade names with accompanying generic names. Trade and generic names may differ in other markets.
Links to more details on the European Medicines Agency's (EMA) webpage are provided for those products that have been granted a central marketing authorisation by the European Commission.
* in the US approved under the brand name Xultophy® 100/3.6.
** in the US called NovoLog®
*** in the US spelt Novoeight®
**** in the US approved under the name of REBINYN®